Category: ARC News

COVID-19 has impacted everyone. Patients with amyloidosis may be at greater risk than the general population. In this frequently updated post, ARC provides the latest recommendations and resources. (more…)

July 7, 2021 CRISPR technology offers a cutting-edge approach to gene-editing. New clinical findings from Intellia’s Phase 1 trial have demonstrated for the first time that CRISPR can be administered by infusion to target specific cells within the body. (more…)

A Report from ISA 2020 Every 2 years, amyloidosis researchers and physicians from all around the world engage in a week-long meeting, the International Symposium on Amyloidosis (ISA). (more…)

Quality and reliable information has always been a focus of the Amyloidosis Research Consortium (ARC). When patients are first diagnosed, it’s hard to know where to turn to learn about your options and what may lie ahead. (more…)

ARC has published a Health Technology Assessment Toolkit to equip patients and patient groups within Europe, as well as globally, with the tools to advocate on behalf of themselves and other patients for access to new treatments. (more…)